Download Cancer - pcori

PATIENT-CENTERED OUTCOMES
RESEARCH INSTITUTE
®
1828 L STREET NW, SUITE 900
WASHINGTON, DC 20036
202.827.7700
RESEARCH SPOTLIGHT ON
Cancer
There are more than 100 kinds of cancer, each with a distinct pathology and a unique blend
of hereditary and environmental triggers. The Centers for Disease Control and Prevention
predicts that 1.69 million people were diagnosed with cancer in the United States in
2016. Even patients with the most common cancers—such as breast, prostate, lung, and
colorectal cancer—are faced with several treatment options and little consensus on what
will work best given their individual circumstances and preferences.
The impact of these illnesses extends far beyond mortality. Cancer can place severe physical, emotional, and financial
burdens on patients and their families. Public health officials estimate that the direct medical costs for cancer in the U.S.
were $88.7 billion in 2011.
As of March 2017, PCORI has awarded
194
$
MILLION TO FUND
65
comparative clinical effectiveness research studies
and methods projects related to cancer
Building a Robust Research Portfolio
PCORI funds comparative clinical effectiveness research (CER) that helps people make better-informed healthcare
choices by finding out which healthcare options work best for which patients, based on their needs and preferences.
PCORI is funding a broad portfolio of research that addresses the full continuum of cancer care, from prevention and
diagnosis to treatment and recovery.
BY THE NUMBERS
By number of projects
Most Studied Cancer Types
18
Breast
Lung
9
Prostate
9
10
6
Nonspecific
10
5
Cervical
Ovarian
4
10
Colorectal
Most Studied Populations
of Interest
Areas of Care Addressed
2
Racial/Ethnic
Minorities
26
Women
Prevention
Screening
Older Adults
Diagnosis
Low Income
Treatment
Survivorship
23
22
14
Urban
40
Rural
Low Literacy/
Numeracy
2
45
PCORI.ORG
|
9
8
[email protected]
|
FOLLOW US @PCORI
Engaging the Community in Research
PCORI works with patients, clinicians, and other members of the healthcare community to ensure that we fund topics
and deliver evidence relevant to patient care. Guidance from stakeholders has helped focus our portfolio of cancer
research on critical questions and outcomes.
PCORI’s Advisory Panel on Addressing Disparities prioritized comparing the effectiveness of breast MRI and
mammography in screening. We included the topic in an April 2013 funding announcement, and it is now being studied
by researchers at Group Health Cooperative in Washington State.
PCORI’s Advisory Panel on the Assessment of Prevention, Diagnosis, and Treatment Options prioritized comparing
robotic surgery and traditional techniques for treating urologic and gynecologic cancers. The University of North
Carolina received PCORI funding in 2014 to compare options for treating prostate cancer.
Building Capacity for Patient-Centered Research
PCORI is investing in people and infrastructure to support highquality patient-centered research for years to come.
PCORnet, the National
Patient-Centered Clinical
Research Network, will
enable us to learn from
the data and experiences of more than 145 million Americans.
It is building capacity for cancer research and other studies by
supporting patient-driven networks and helping them connect with
researchers who are studying similar topics.
For example, one patient-powered network, ABOUT PPRN, will
provide a critical resource for studies of hereditary cancer. It is
enrolling people with a family or personal history of cancer who
have undergone genetic testing for inherited mutations in genes
such as BRCA, PALB2, and PTEN, which are associated with a high
risk for specific cancers.
Bringing Patients Together
to Drive Research
The ABOUT PPRN has enrolled 8,000 patients
in its registry and continues to grow. It
will enable faster, more accurate research
on hereditary cancer. ABOUT has formed
partnerships with:
• Black Women’s Health Imperative
• Ovarian Cancer Research Fund Alliance
• Sharsheret
• Young Survival Coalition
STUDY SPOTLIGHT
The Wisdom Study:
Annual Breast Cancer Screening versus Personalized Schedules
Not every woman has the same risk for breast cancer, but guidelines call for all women to follow the same
screening schedules. A personalized approach could improve outcomes. PCORI-funded researchers are studying
several questions about screening:
• What are the safest, most effective screening strategies?
• How can we reduce false-positive results and overdiagnosis?
• How can we ensure each woman receives screenings and prevention strategies appropriate for her
individual risk?
LEAD RESEARCHER: Laura J. Esserman, MBA, MD, University of California, San Francisco
ENGAGEMENT PARTNERS: American Cancer Society, Cancer CAREpoint, Community Mammography Access Project,
Zero Breast Cancer, FORCE, LIVESTRONG Foundation, National Breast Cancer Coalition, and Susan G. Komen
YEAR APPROVED: 2015
PROJECT BUDGET: $14.1 million
UPDATED MARCH 2017
|
RESEARCH DONE DIFFERENTLY®